Vision protection therapy for prevention of neovascular age-related macular degeneration

Scientific Reports · 3 authors, 3 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This retrospective cohort study analyzed real-world data from US retina clinics to compare the progression from dry to wet AMD in eyes receiving Vision Protection Therapy (VPT) versus standard care alone (SCA). After matching for risk factors, eyes in the VPT group had a significantly lower rate of conversion to wet AMD compared to the SCA group.

Full summary

447 CHARS

This study analyzed aggregated, de-identified data from over 320 US retina specialists to compare the risk of neovascular conversion in dry AMD. 737 VPT eyes). Analysis without encounter matching showed a similar hazard ratio of 5.73. The authors note the study's retrospective design and potential residual imbalances favoring the SCA group. The results suggest VPT may be markedly more effective than standard care at preventing neovascular AMD.

STUDY TYPE

cohort

SPECIALTY

ophthalmology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10550910

Vision protection therapy for prevention of neovascular age-related macular degeneration

Scientific Reports

READ THE FULL PAPER

ABSTRACT

To access the effect of vision protection therapy on neovascular conversion in age-related macular degeneration (AMD). Patient unidentified data aggregated by Vestrum Health, LLC (VH) from over 320 US retina specialists was analyzed to compare the conversion rate from dry to neovascular (wet) AMD in a practice employing VPT (VPT group) compared to those employing standard care alone (SCA group) between January 2017 through July 2023. 500,00 eyes were filtered then matched for neovascular conversion risk factors by propensity scoring and compared in a 10/1 ratio of 7370 SCA and 737 VPT treated eyes. SCA eyes had significantly fewer clinical encounters and shorter follow up than the VPT group. Despite this, the risk of neovascular conversion by PS was significantly lower in the VPT group compared to SCA (HR 5.73, p < 0.0001). Analysis matching the encounter frequency of both groups as a post-randomization variable produced a similar HR (HR 5.98, p < 0.0001). Because 9% of eyes in the VPT group were not treated with VPT due to bilateral early (low-risk) AMD, analysis comparing the SCA group to VPT-treated eyes was done that also showed significantly lower conversion rates in the VPT-treated eyes, with or without encounter frequency matching (HR 5.84, 5.65, p < 0.0001). Visual acuity was consistently better in VPT eyes compared to SCA eyes throughout the study time window. The advantage of VPT over SCA increased with increased SCA encounter frequency and higher conversion risk factors, including age and ICD10 coded dry AMD severity. Neovascular (wet) AMD is the main cause of irreversible visual loss worldwide. Consistent with two prior studies, the current study finds Vision Protection Therapy markedly more effective at both recognizing and preventing neovascular AMD than the current standard of care, benefiting the highest risk dry AMD eyes the most.

CITATION EXPORT

Jeffrey K. Luttrull, Gerry Gray, Sathy V. Bhavan. Vision protection therapy for prevention of neovascular age-related macular degeneration. Scientific Reports. (2023). https://doi.org/10.1038/s41598-023-43605-w

AUTHORS

3 · 3 CENTRES

Jeffrey K. Luttrull, Gerry Gray, Sathy V. Bhavan

1Ventura County Retina Vitreous Medical Group, Ventura, CA USA
2Regulatory Pathways, Inc, Laguna Beach, CA USA
3Ventura County Retina Vitreous Medical Group, 3160 Telegraph Rd, Suite 230, Ventura, CA 93003 USA